Form 4: Neuphoria CEO Granted Stock Options

Neuphoria Therapeutics Inc. President and CEO, Spyros Papapetropoulos, was granted 34,559 employee stock options with an exercise price of $8.27.

Summary

• Spyros Papapetropoulos, President and CEO of Neuphoria Therapeutics Inc. (NEUP), was granted 34,559 employee stock options.
• The options have an exercise price of $8.27 per share.
• The transaction date for this grant was August 27, 2025.
• The options will vest on a monthly basis over a four-year period, at a rate of 2.0833% of the shares on the last day of each month, starting from August 1, 2025.
• The options have an expiration date of August 27, 2035.
• Following this transaction, Mr. Papapetropoulos beneficially owns 74,088 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates management alignment and retention, which are generally favorable for investors, despite the potential for future dilution.

Positives

• The grant of stock options aligns the interests of the President and CEO with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from key management over a four-year period.

Negatives

• Potential future dilution for existing shareholders if the options are exercised, although this is a standard aspect of equity compensation.

Risks

• The value of the options is subject to the future market price of Neuphoria Therapeutics Inc. common stock; if the stock price remains below the exercise price of $8.27, the options may not be in-the-money.
• The options are subject to forfeiture if the reporting person's continuing service with the company ceases before full vesting.

Future Outlook

The vesting schedule of the options, extending over a four-year period, indicates an expectation of continued service from the President and CEO, Spyros Papapetropoulos, through at least August 2029.

Industry Context

The grant of stock options to a President and CEO is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate top talent while aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as a form of executive compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The four-year vesting schedule is typical for executive equity grants, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their executive incentive programs, which often feature multi-year vesting to ensure long-term commitment.

Stakeholder Impact

• Shareholders: The grant of options can align management's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if the options are exercised.
• Employees: This transaction is specific to the CEO, but it reflects the company's approach to executive compensation, which can influence broader employee incentive programs.

Next Steps

• Spyros Papapetropoulos's continued service with Neuphoria Therapeutics Inc. is required for the options to vest according to the monthly schedule over the next four years.

Key Dates

Keywords

Neuphoria Therapeutics, NEUP, Stock Options, Executive Compensation, Insider Transaction, Form 4, Spyros Papapetropoulos, CEO, Director